Carvolix SA (EPA:CVX)

Market Cap	199.65M +262.4%
Revenue (ttm)	900.00K -83.2%
Net Income	-24.97M
EPS	n/a
Shares Out	59.24M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,087
Average Volume	29,621
Open	3.430
Previous Close	3.450
Day's Range	3.160 - 3.450
52-Week Range	1.160 - 5.220
Beta	1.06
RSI	53.61
Earnings Date	Apr 24, 2026

About Carvolix

Carvolix SA, a medical technology company, develops and markets minimally invasive minimally invasive medical devices in the field of urology and structural heart in France. It offers Artus, an implantable electro-mechanical artificial sphincter that targets moderate to severe urinary incontinence; and Kalios and Epygon implants for the treatment of mitral insufficiency, as well as Kardiozis technology for treating abdominal aortic aneurysm. The company was formerly known as Affluent Medical SA and changed its name to Carvolix SA in February 20...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2011
• Employees: 68
• Stock Exchange: Euronext Paris
• Ticker Symbol: CVX

Financial Performance

In 2025, Carvolix's revenue was 900,000, a decrease of -83.18% compared to the previous year's 5.35 million. Losses were -24.97 million, 69.4% more than in 2024.